Floatz logo

Glycyrrhizic acid

HCC

The First Affiliated Hospital of Zhengzhou UniversitySmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the HCC cohort.

Asset / SponsorPhaseRating
EOB-DTPA
Charite University, Berlin, Germany
Phase 4BB
CARVEDILOL
Tongji Hospital
Phase 4BB
Hepcortespenlisimut-L
Immunitor LLC
Phase 3B
Tirelizumab
Chen Xiaoping
Phase 4B
ASCRINVACUMAB
Suzhou Kintor Pharmaceutical Inc,
Phase 2B

View all 38 →

Same molecule, other indications

Glycyrrhizic acid is also rated in:

prostate cancerDormant
CC
Indicative ·
46 / 100
View asset →
biliary atresiaDormant
D
Indicative ·
30 / 100
View asset →
cholangitisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →